Literature DB >> 15519621

Should rosuvastatin be withdrawn from the market?

Stefan R Florentinus, Eibert R Heerdink, Olaf H Klungel, Anthonius de Boer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15519621     DOI： 10.1016/S0140-6736(04)17301-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.

Authors:  Jung-Im Shin; Derek M Fine; Yingying Sang; Aditya Surapaneni; Stephan C Dunning; Lesley A Inker; Thomas D Nolin; Alex R Chang; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2022-07-19       Impact factor: 14.978

2.  Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision.

Authors:  G Trifirò; M Alacqua; S Corrao; S Moretti; D U Tari; M Galdo; A P Caputi; V Arcoraci
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

3.  Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.

Authors:  Toshiyuki Sakaeda; Kaori Kadoyama; Yasushi Okuno
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

4.  National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.

Authors:  Azuana Ramli; Syed Mohamed Aljunid; Saperi Sulong; Faridah Aryani Md Yusof
Journal:  Ther Clin Risk Manag       Date:  2013-12-04       Impact factor: 2.423

5.  Is new drug prescribing in primary care specialist induced?

Authors:  Stefan R Florentinus; Eibert R Heerdink; Liset van Dijk; A M G Fabiënne Griens; Peter P Groenewegen; Hubert G M Leufkens
Journal:  BMC Health Serv Res       Date:  2009-01-11       Impact factor: 2.655

6.  Evidence-based prescribing of statins: a developing world perspective.

Authors:  H T Ong
Journal:  PLoS Med       Date:  2006-02-21       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.